Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Depression 4Polycystic Ovary Syndrome 2Depressive Disorder, Major 2Neoplasms 1Lymphoma, Follicular 1Hot Flashes 1Head and Neck Neoplasms 1ENT Cancer 1Breast Neoplasms 1Asthma 1

Interventions

Gabapentin 6Acupuncture Therapy 4Venlafaxine Hydrochloride 3liposomal amphotericin B 2Tamoxifen 2Magnesium Oxide 2Isoflavones 2Citalopram 2Caspofungin 2zopiclone 1oxybutynin 1black cohosh root extract 1Zolpidem 1Vitamin B 6 1Vancomycin 1Testosterone 1Tazobactam 1Soybean Proteins 1Sodium Chloride 1Sertraline 1Pregabalin 1Piperacillin, Tazobactam Drug Combination 1Piperacillin 1N,N'-(1,4-phenylenebis(methylene))dipyrimidin-2-amine 1Moxifloxacin 1Mindfulness-Based Stress Reduction 1Mindfulness 1Mind-Body Therapies 1Megestrol Acetate 1Medroxyprogesterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hot Flashes × Escitalopram × Clear all
NCT00667121 2025-02-14

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Mayo Clinic

Completed
88 enrolled
Breast

Breast Neoplasms, Depression, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡